In this episode, I have an insightful conversation with Chris Hart, the CEO of Creyon Bio, to dive into how artificial intelligence is reshaping drug development. Creyon Bio is pioneering the use of AI to engineer Oligonucleotide-Based Medicines (OBMs), prioritizing safety in their approach to creating effective treatments. By applying cutting-edge technology, the company is able to streamline the identification of safe medicines, offering a more efficient path to drug discovery. One of the most compelling examples of their work is the recent treatment of a baby boy diagnosed with an ultra-rare disease caused by a mutation in the TNPO2 gene. In just 13 months, Creyon Bio developed a tailored treatment that marked a major milestone in the world of personalized medicine. Chris shares the story of this breakthrough, highlighting the role AI played in rapidly creating and testing a selective lock nucleic acid (LNA) antisense oligo, which led to significant improvements in the child's health. We also explore how Creyon Bio’s AI-driven platform addresses common challenges in drug development, from enhancing safety to optimizing delivery. Chris delves into how AI helps analyze complex data sets, enabling the rapid progression from identifying a target to developing a lead compound. This innovation is not only revolutionizing timelines but also increasing the probability of success in the often unpredictable world of biotech. Tune in to hear Chris’s valuable insights on the future of AI in medicine, the challenges the industry faces, and how Creyon Bio is pushing the boundaries of what’s possible in drug engineering. Could AI be the key to accelerating life-saving treatments for rare diseases?